In this single-arm, phase II trial, researchers sought to evaluate the effectiveness of the combination of nivolumab (nivo) plus ipilimumab (ipi) as a first-line therapy with respect to the 12-month overall survival (OS) in patients with metastatic uveal melanoma (MUM) who are not eligible for liver resection.
Publications
Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival
Thromboembolism (TE) in cancer significantly contributes to morbidity and mortality. Little is known about the incidence of arterial TE (ATE) and venous TE (VTE) in patients with melanoma on immune checkpoint inhibitor (ICI) therapy.
The Yin and Yang of BRAF, MEK and CDK4-6 targeted therapy
A new paper from the McArthur & Sheppard Laboratory, by Emily Lelliott et. al.
Damage-associated molecular pattern (DAMP) activation in melanoma: investigation of the immunogenic activity of 15-deoxy, Δ12,14 prostamide J2
Metastatic melanoma is the most deadly skin neoplasm in the United States.